Corticosteroids compromise survival in glioblastoma

Brain

Volumn 139, Issue 5, 2016, Pages 1458-1471

  Pitter, Kenneth L ^a   Tamagno, Ilaria ^b   Alikhanyan, Kristina ^c   Hosni Ahmed, Amira ^d   Pattwell, Siobhan S ^e   Donnola, Shannon ^b   Dai, Charles ^b   Ozawa, Tatsuya ^e   Chang, Maria ^a   Chan, Timothy A ^a   Beal, Kathryn ^a   Bishop, Andrew J ^a   Barker, Christopher A ^a   Jones, Terreia S ^d   Hentschel, Bettina ^f   Gorlia, Thierry ^g   Schlegel, Uwe ^h   Stupp, Roger ⁱ   Weller, Michael ^j   Holland, Eric C ^e,k   Hambardzumyan, Dolores ^b,c   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^e USA   (United States)

^f UNIVERSITY OF LEIPZIG   (Germany)

^g EORTC DATA CENTER   (Belgium)

^h RUHR UNIVERSITY BOCHUM   (Germany)

ⁱ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^j UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^k UNIVERSITY OF WASHINGTON   (United States)

more..

Author keywords

astrocytoma; CNS tumour: surgical treatment; genetics; glioma; neurooncology

Indexed keywords

DEXAMETHASONE; TEMOZOLOMIDE; VASCULOTROPIN; ANTIBODY; CORTICOSTEROID; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER RADIOTHERAPY; CELL DEATH; CELL INFILTRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; COHORT ANALYSIS; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION; GENE IDENTIFICATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; SURVIVAL TIME; TUMOR CELL; TUMOR VASCULARIZATION; ADVERSE EFFECTS; ANIMAL; BRAIN NEOPLASMS; DRUG EFFECTS; FEMALE; IMMUNOLOGY; MALE; MORTALITY; MULTIMODALITY CANCER THERAPY; SURVIVAL ANALYSIS; TRANSGENIC MOUSE;

ADRENAL CORTEX HORMONES; ANIMALS; ANTIBODIES; BRAIN NEOPLASMS; CELL DEATH; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DEXAMETHASONE; FEMALE; GENE EXPRESSION; GLIOBLASTOMA; HUMANS; MALE; MICE; MICE, TRANSGENIC; RADIOTHERAPY; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84966560449     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aww046     Document Type: Article

References (36)

1. Becher OJ, Hambardzumyan D, Fomchenko EI, Momota H, Mainwaring L, Bleau AM, et al. Gli activity correlates with tumor grade in platelet-derived growth factor-induced gliomas. Cancer Res 2008; 68: 2241-9.
2. Eisenberg HM, Barlow CF, Lorenzo AV. Effect of dexamethasone on altered brain vascular permeability. Arch Neurol 1970; 23: 18-22.
3. Ellsworth S, Grossman SA. Comment on 'Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma'. Br J Cancer 2015; 113: 1632-3.
4. Feng X, Szulzewsky F, Yerevanian A, Chen Z, Heinzmann D, Rasmussen RD, et al. Loss of CX3CR1 increases accumulation of inflammatory monocytes and promotes gliomagenesis. Oncotarget 2015; 6: 15077-94.
5. Gerstner ER, Duda DG, di Tomaso E, Ryg PA, Loeffler JS, Sorensen AG, et al. VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat Rev Clin Oncol 2009; 6: 229-36.
6. Glaser T, Wagenknecht B, Weller M. Identification of p21 as a target of cycloheximide-mediated facilitation of CD95-mediated apoptosis in human malignant glioma cells. Oncogene 2001; 20: 4757-67.
7. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 2008; 9: 29-38.
8. Grasso RJ, Johnson CE, Boler RK, Moore NA. Combined growthinhibitory responses and ultrastructural alterations produced by 1,3-bis(2-chloroethyl)-1-nitrosourea and dexamethasone in rat glioma cell cultures. Cancer Res 1977; 37: 585-94.
9. Hambardzumyan D, Amankulor NM, Helmy KY, Becher OJ, Holland EC. Modeling adult gliomas using RCAS/t-va technology. Transl Oncol 2009; 2: 89-95.
10. Hambardzumyan D, Becher OJ, Rosenblum MK, Pandolfi PP, Manova-Todorova K, Holland EC. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev 2008; 22: 436-48.
11. Hambardzumyan D, Gutmann DH, Kettenmann H. The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci 2015; 19: 20-7.
12. Helmy K, Halliday J, Fomchenko E, Setty M, Pitter K, Hafemeister C, et al. Identification of global alteration of translational regulation in glioma in vivo. PloS One 2012; 7: e46965
13. Kamoun WS, Ley CD, Farrar CT, Duyverman AM, Lahdenranta J, Lacorre DA, et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 2009; 27: 2542-52.
14. Kempf H, Hatzikirou H, Bleicher M, Meyer-Hermann M. In silico analysis of cell cycle synchronisation effects in radiotherapy of tumour spheroids. PLoS Comp Bio 2013; 9: 1-14.
15. Kokunai T, Tamaki N. Relationship between expression of p21WAF1/CIP1 and radioresistance in human gliomas. Jpn J Cancer Res 1999; 90: 638-46.
16. Kostaras X, Cusano F, Kline GA, Roa W, Easaw J. Use of dexamethasone in patients with high-grade glioma: a clinical practice guideline. Curr Oncol 2014; 21: e493-503.
17. Kotsarini C, Griffiths PD, Wilkinson ID, Hoggard N. A systematic review of the literature on the effects of dexamethasone on the brain from in vivo human-based studies: implications for physiological brain imaging of patients with intracranial tumors. Neurosurgery 2010; 67: 1799-815; discussion 815.
18. Koutcher JA, Hu X, Xu S, Gade TP, Leeds N, Zhou XJ, et al. MRI of mouse models for gliomas shows similarities to humans and can be used to identify mice for preclinical trials. Neoplasia 2002; 4: 480-5.
19. Naumann U, Durka S, Weller M. Dexamethasone-mediated protection from drug cytotoxicity: association with p21WAF1/CIP1 protein accumulation Oncogene 1998; 17: 1567-75.
20. Nestler U, Winking M, Boker DK. The tissue level of dexamethasone in human brain tumors is about 1000 times lower than the cytotoxic concentration in cell culture. Neurol Res 2002; 24: 479-82.
21. Parr MJ, Manome Y, Tanaka T, Wen P, Kufe DW, Kaelin WG Jr., et al. Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat Med 1997; 3: 1145-9.
22. Piette C, Munaut C, Foidart JM, Deprez M. Treating gliomas with glucocorticoids: from bedside to bench. Acta Neuropathol 2006; 112: 651-64.
23. Powell SN, Abraham HE. The Biology of radioresistance: similarities, differences and interactions with drug resiastance. In: Clynes M, editor. Multiple drug resistance in cancer: cellular, molecular and clinial approaches. 1994. p. 325-47.
24. Raslan A, Bhardwaj A. Medical management of cerebral edema. Neurosurg Focus 2007; 22: E12
25. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008; 22: 659-61.
26. Rovit RL, Hagan R. Steroids and cerebral edema: the effects of glucocorticoids on abnormal capillary permeability following cerebral injury in cats. J Neuropathol Exp Neurol 1968; 27: 277-99.
27. Sandmann T, Bourgon R, Garcia J, Li C, Cloughesy T, Chinot OL, et al. Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: retrospective analysis of the AVAglio trial. J Clin Oncol 2015; 33: 2735-44.
28. Shields LB, Shelton BJ, Shearer AJ, Chen L, Sun DA, Parsons S, et al. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients. Radiat Oncol 2015; 10: 222.
29. Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 1100-8.
30. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.
31. Ueda S, Mineta T, Nakahara Y, Okamoto H, Shiraishi T, Tabuchi K. Induction of the DNA repair gene O6-methylguanine-DNA methyltransferase by dexamethasone in glioblastomas. J Neurosurg 2004; 101: 659-63.
32. Uhrbom L, Nerio E, Holland EC. Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model. Nat Med 2004; 10: 1257-60.
33. Verhoeff JJ, van Tellingen O, Claes A, Stalpers LJ, van Linde ME, Richel DJ, et al. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 2009; 9: 444.
34. Wang H, Li M, Rinehart JJ, Zhang R. Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy. Clin Cancer Res 2004; 10: 1633-44.
35. Weller M, Schmidt C, Roth W, Dichgans J. Chemotherapy of human malignant glioma: prevention of efficacy by dexamethasone Neurology 1997; 48: 1704-9.
36. Wong ET, Lok E, Gautam S, Swanson KD. Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma. Br J Cancer 2015; 113: 1642.